Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEH3O7)

Drug Name
Rifamycin Drug Info
Synonyms
Rifamycin SV; Rifamycin SV MMX; Rifamycin sodium; CB-01-11; Rifamycin (oral controlled-release, gastrointestinal-specific); Rifamycin (oral controlled-release, gastrointestinal-specific), Cosmo/Dr Falk/Santarus
Indication
Disease Entry ICD 11 Status REF
Diarrhea ME05.1 Approved [1]
Infectious disease 1A00-CA43.1 Phase 3 [2]
Cross-matching ID
PubChem CID
6324616
ChEBI ID
CHEBI:29673
CAS Number
CAS 6998-60-3
TTD Drug ID
DMEH3O7
VARIDT Drug ID
DR00614
ACDINA Drug ID
D01389

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Mycobacterium RNA polymerase (MycB RNAP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Favipiravir DMBZ27L Influenza virus infection 1E30-1E32 Registered [8]
TAS-106 DML97KB Head and neck cancer 2D42 Phase 2 [9]
JTK-003 DMB0V5Y Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [10]
R-1479 DM9C6LN Hepatitis C virus infection 1E51.1 Discontinued in Phase 1 [11]
XTL-2125 DM3Y6M7 Hepatitis C virus infection 1E51.1 Discontinued in Phase 1 [12]
Drug(s) Targeting Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tagetitoxin DM3B8R1 Discovery agent N.A. Investigative [13]
Myxopyronin B DM16SVM Discovery agent N.A. Investigative [14]
Drug(s) Affected By Glutathione S-transferase A1 (GSTA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Artemisinin DMOY7W3 Malaria 1F40-1F45 Approved [15]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [16]
Thiotepa DMIZKOP Breast cancer 2C60-2C65 Approved [17]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [18]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [19]
Ethacrynic acid DM60QMR Edema MG29 Approved [20]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [21]
Busulfan DMXYJ9C Chronic myelogenous leukaemia 2A20.0 Approved [22]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [23]
Methotrexate DM2TEOL Anterior urethra cancer Approved [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Glutathione S-transferase Mu 1 (GSTM1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Busulfan DMXYJ9C Chronic myelogenous leukaemia 2A20.0 Approved [25]
Azathioprine DMMZSXQ Lupus nephritis 4A40.0Y Approved [26]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [27]
Ethanol DMDRQZU Chronic pain MG30 Approved [28]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [29]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [29]
Methyldopa DM5I621 Hypertension BA00-BA04 Approved [30]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [31]
Testosterone DM7HUNW Hot flushes GA30 Approved [32]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier organic anion transporter family member 1B1 (SLCO1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Enalapril DMNFUZR Congestive heart failure BD10 Approved [33]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [6]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [34]
Repaglinide DM5SXUV Diabetic complication 5A2Y Approved [35]
Methotrexate DM2TEOL Anterior urethra cancer Approved [36]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [37]
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [38]
Ursodeoxycholic acid DMCUT21 Cholelithiasis DC11 Approved [38]
Hydroxyurea DMOQVU9 Chronic myelogenous leukaemia 2A20.0 Approved [39]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [40]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By C-reactive protein (CRP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lidocaine DML4ZOT Anaesthesia 9A78.6 Approved [41]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [42]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [43]
Quercetin DM3NC4M Obesity 5B81 Approved [44]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [45]
Acalabrutinib DM7GCVW leukaemia 2A60-2B33 Approved [46]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [47]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [48]
Tibolone DM78XFG Anabolic metabolism 5C50-5C8Z Approved [49]
Testosterone DM7HUNW Hot flushes GA30 Approved [50]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier organic anion transporter family member 1B3 (SLCO1B3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Warfarin DMJYCVW Atrial fibrillation BC81.3 Approved [51]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [52]
Hydroxyurea DMOQVU9 Chronic myelogenous leukaemia 2A20.0 Approved [39]
Trospium chloride DM32XZT Discovery agent N.A. Approved [53]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [54]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [45]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [55]
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [54]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [56]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [57]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial RNA polymerase sigma factor SigA (Bact sigA) TTR6YA2 SIGA_STAA8 Modulator [3]
Mycobacterium RNA polymerase (MycB RNAP) TT79JGK RPOA_MYCTU; RPOB_MYCTU; RPOC_MYCTU; RPOZ_MYCTU Inhibitor [1]
Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB) TTS31JH RPOB_STAA8 Modulator [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Gene/Protein Processing [4]
Glutathione S-transferase A1 (GSTA1) OTA7K5XA GSTA1_HUMAN Gene/Protein Processing [5]
Glutathione S-transferase Mu 1 (GSTM1) OTSBF2MO GSTM1_HUMAN Gene/Protein Processing [5]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1) OTNEN8QK SO1B1_HUMAN Gene/Protein Processing [6]
Solute carrier organic anion transporter family member 1B3 (SLCO1B3) OTOM3BUH SO1B3_HUMAN Gene/Protein Processing [7]

References

1 Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4832-E4840.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4570).
3 NCBI report
4 Multiple intra-articular treatment of rheumatoid arthritis: a randomized prospective study comparing rifamycin SV with pefloxacin. J Int Med Res. 1992 Feb;20(1):27-39. doi: 10.1177/030006059202000104.
5 The influence of picolines on glutathione transferase activity and subunit composition in human liver derived Hep G2 cells. Biochem Pharmacol. 1994 Nov 16;48(10):1976-8.
6 Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
7 Neonicotinoid pesticides poorly interact with human drug transporters. J Biochem Mol Toxicol. 2019 Oct;33(10):e22379. doi: 10.1002/jbt.22379. Epub 2019 Jul 31.
8 Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral Res.2013 Nov;100(2):446-54.
9 Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.Invest New Drugs.2012 Feb;30(1):316-26.
10 Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care. Viruses. 2010 April; 2(4): 826-866.
11 The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cel... J Biol Chem. 2006 Feb 17;281(7):3793-9.
12 DOI: 10.1111/j.1365-2036.2009.03927.x
13 Synthesis of the bicyclic core of tagetitoxin. Chem Commun (Camb). 2006 Mar 21;(11):1197-9.
14 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
15 Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer. 2002 Feb 10;97(5):700-5.
16 Human glutathione S-transferase A (GSTA) family genes are regulated by steroidogenic factor 1 (SF-1) and are involved in steroidogenesis. FASEB J. 2013 Aug;27(8):3198-208. doi: 10.1096/fj.12-222745. Epub 2013 May 6.
17 Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Br J Clin Pharmacol. 2009 Jan;67(1):50-60. doi: 10.1111/j.1365-2125.2008.03321.x. Epub 2008 Nov 17.
18 Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices. Toxicol Sci. 2001 Jan;59(1):118-26.
19 Acetaminophen-induced hepatocyte injury: C2-ceramide and oltipraz intervention, hepatocyte nuclear factor 1 and glutathione S-transferase A1 changes. J Appl Toxicol. 2019 Dec;39(12):1640-1650. doi: 10.1002/jat.3881. Epub 2019 Aug 6.
20 Antineoplastic drug sensitivity of human MCF-7 breast cancer cells stably transfected with a human alpha class glutathione S-transferase gene. Cancer Res. 1991 Jan 15;51(2):587-94.
21 Establishment of cisplatin-resistant ovarian yolk sac tumor cells and investigation of the mechanism of cisplatin resistance using this cell line. Gynecol Obstet Invest. 2011;71(2):104-11. doi: 10.1159/000320744. Epub 2010 Dec 9.
22 Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression. Br J Pharmacol. 2002 Dec;137(7):1100-6. doi: 10.1038/sj.bjp.0704972.
23 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
24 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
25 Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2010 Dec 1;55(6):1172-9. doi: 10.1002/pbc.22739.
26 Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007 Jan;13(1):57-64. doi: 10.1002/ibd.20004.
27 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
28 Association of polymorphism in alcohol dehydrogenase and interaction with other genetic risk factors with alcoholic liver cirrhosis. Drug Alcohol Depend. 2010 Jun 1;109(1-3):190-7. doi: 10.1016/j.drugalcdep.2010.01.010. Epub 2010 Feb 18.
29 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
30 Inhibition of human glutathione S-transferases by dopamine, alpha-methyldopa and their 5-S-glutathionyl conjugates. Chem Biol Interact. 1994 Jan;90(1):87-99.
31 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
32 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
33 Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Clin Ther. 2011 May;33(5):655-63. doi: 10.1016/j.clinthera.2011.04.018.
34 Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
35 Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 Jun;77(6):468-78. doi: 10.1016/j.clpt.2005.01.018.
36 SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014 Nov;142(1):196-209. doi: 10.1093/toxsci/kfu162. Epub 2014 Aug 14.
37 SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99.
38 Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006 Jun;47(6):1196-202.
39 Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
40 Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit. 2007 Oct;29(5):666-8. doi: 10.1097/FTD.0b013e3181357364.
41 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
42 C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS. 2004 Dec 3;18(18):2434-7.
43 Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension. 2004 Aug;44(2):180-5. doi: 10.1161/01.HYP.0000133310.42762.25. Epub 2004 Jun 7.
44 The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. Eur J Pharmacol. 2007 Feb 28;557(2-3):221-9.
45 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
46 Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020 Jun 5;5(48):eabd0110. doi: 10.1126/sciimmunol.abd0110. Epub 2020 Jun 5.
47 The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis. Curr Med Res Opin. 1975;3(5):286-97. doi: 10.1185/03007997509114779.
48 Intractable insomnia after cessation of treatment with thalidomide. Gastroenterology. 2001 May;120(6):1567-8. doi: 10.1053/gast.2001.24495.
49 Effects of hormone treatment on hemostasis variables. Climacteric. 2007 Oct;10 Suppl 2:32-7. doi: 10.1080/13697130701598548.
50 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
51 Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population. Sci Rep. 2017 Dec 12;7(1):17379. doi: 10.1038/s41598-017-17731-1.
52 Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83.
53 Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
54 Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
55 Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
56 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
57 Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005.